@article{7827937b15f94a718638f5cfaa53c550,
title = "The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease",
abstract = "Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may also be beneficial in the treatment of inflammatory diseasest1-3. Atorvastatin (Lipitor) was tested in chronic and relapsing experimental autoimmune encephalomyelitis, a CD4+ Th1-mediated central nervous system (CNS) demyelinating disease model of multiple sclerosis4'5. Here we show that oral atorvastatin prevented or reversed chronic and relapsing paralysis. Atorvastatin induced STAT6 phosphorylation and secretion of Th2 cytokines (interleukin (IL)-4, IL-5 and IL-10) and transforming growth factor (TGF)-β. Conversely, STAT4 phosphorylation was inhibited and secretion of Th1 cytokines (IL-2, IL-12, interferon (IFN)-γ and tumour necrosis factor (TNF)-α) was suppressed. Atorvastatin promoted differentiation of Th0 cells into Th2 cells. In adoptive transfer, these Th2 cells protected recipient mice from EAE induction. Atorvastatin reduced CNS infiltration and major histocompatibility complex (MHC) class II expression. Treatment of microglia inhibited IFNgamma;-inducible transcription at multiple MHC class II transactivator (CIITA) promoters and suppressed class II upregulation. Atorvastatin suppressed IFNγ-inducible expression of CD40, CD80 and CD86 co-stimulatory molecules. L-Mevalonate, the product of HMG-CoA reductase, reversed atorvastatin's effects on antigen-presenting cells (APC) and T cells. Atorvastatin treatment of either APC or T cells suppressed antigen-specific T-cell activation. Thus, atorvastatin has pleiotropic immunomodulatory effects involving both APC and T-cell compartments. Statins may be beneficial for multiple sclerosis and other Th1-mediated autoimmune diseases.",
author = "Sawsan Youssef and Olaf St{\"u}ve and Patarroyo, {Juan O.} and Ruiz, {Pedro J.} and Radosevich, {Jennifer L.} and {Mi Hur}, Eun and Manuel Bravo and Mitchell, {Dennis J.} and Sobel, {Raymond A.} and Lawrence Stelnman and Zamvil, {Scott S.}",
note = "Funding Information: Acknowledgements We thank S. Birren and M. Chao for providing some of the p75 mutant mice and constructs; K. Gerhold for technical assistance; K.-F. Lee for discussion; and M. Greenberg, V. Koprivica and K.-F. Lee for critical reading of the manuscript. This study was supported by the Alfred Sloan Foundation, the Burrough Wellcome Fund, the EJLB Foundation, the International Spinal Research Trust, the John Merck Fund, the Klingenstein Fund, the Whitehall Foundation, the National Institute of Drug Abuse, and the National Institute of Neurological Disorders and Stroke (to Z.H.). K.C.W. is a recipient of a Howard Hughes Predoctoral Fellowship. R.S. is supported by a postdoctoral fellowship from the Lefler Foundation. Funding Information: Acknowledgements We thank J. Bluestone, C. G. Fathman, A. J. Slavin, P. A. Nelson, E. Waubant and W. H. Robinson for discussions, R. Laskey for providing us with purified atorvastatin, and M. J. Eaton and N. A. van Venrooij for technical assistance. Support for this work was provided to S.S.Z. by the Alexander M. and June L. Maisin Foundation, the National Institutes of Health (NIH), the National Multiple Sclerosis Society (NMSS) and the Nancy Davis Foundation. S.S.Z. is a 2002 recipient of an Atorvastatin Research Award form Pfizer Inc., and a research grant from the Wadsworth Foundation. Support was provided to L.S. by the NIH and to R.A.S. by the NMSS. S.Y. is a fellow of the Katherine McCormick Foundation. O.S. is supported by a postdoctoral fellowship from the NMSS.",
year = "2002",
month = nov,
day = "7",
doi = "10.1038/nature01158",
language = "English (US)",
volume = "420",
pages = "78--84",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6911",
}